Thibault De La Motte Rouge

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

Anastasios Stathis, Emanuele Zucca, Mohamed Békradda et al. · Cancer Discovery · 2016 · 381 citations · Full text

Medicine, Oncology, Pharmacology +13

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès et al. · European Urology · 2014 · 165 citations

Medicine, Oncology, Pharmacology +9

A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non–Small Cell Lung Cancer Cells Resistant to Erlotinib

Thibault De La Motte Rouge, Lorenzo Galluzzi, Ken A. Olaussen et al. · Cancer Research · 2007 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17